Figure 4.

Significance of innate immunity in MBT immunotherapy in subcutaneous PHEO. B6.CB17-Prkdc^scid/SzJ mice were subcutaneously injected with MTT-luciferase cells. After tumors grew to the desired size (about 50 mm³), mice were randomized into two groups (n = 6/group): (i) the group treated with MBT and (ii) the group treated with PBS. MBT and PBS were given intratumorally on days 0, 1, 2, 8, 9, 10, 16, 17, 18, 24, 25, and 26. Tumor volume was measured with a caliper. (A) The tumor volume growth is presented as a growth curve (** p < 0.01 against PBS) and (B) as an area under the curve (AUC) (* p < 0.05 against PBS). (C) Surviving mice were sacrificed on the 30th day of therapy (five mice from the MBT-treated group and five mice from the PBS-treated group), and tumors were documented. (D) Hematoxylin and eosin (H&E) staining and CD45⁺ immunohistochemistry staining were performed on tumor cryosections (a thickness of 8 µm). Bar = 20 µm.